|
1
|
Zhou L, Chen Z, Vanderslice P, So SP, Ruan
KH, Willerson JT and Dixon RA: Endothelial-like progenitor cells
engineered to produce prostacyclin rescue monocrotaline-induced
pulmonary arterial hypertension and provide right ventricle
benefits. Circulation. 128:982–994. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cheng GS, Zhang YS, Zhang TT, He L and
Wang XY: Bone marrow-derived mesenchymal stem cells modified with
IGFBP-3 inhibit the proliferation of pulmonary artery smooth muscle
cells. Int J Mol Med. 39:223–230. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Farber HW and Loscalzo J: Pulmonary
arterial hypertension. N Engl J Med. 351:1655–1665. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huertas A, Perros F, Tu L, Cohen-Kaminsky
S, Montani D, Dorfmüller P, Guignabert C and Humbert M: Immune
dysregulation and endothelial dysfunction in pulmonary arterial
hypertension: A complex interplay. Circulation. 129:1332–1340.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tuder RM, Archer SL, Dorfmüller P, Erzurum
SC, Guignabert C, Michelakis E, Rabinovitch M, Schermuly R,
Stenmark KR and Morrell NW: Relevant issues in the pathology and
pathobiology of pulmonary hypertension. J Am Coll Cardiol. 62 25
Suppl:D4–D12. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ranchoux B, Antigny F, Rucker-Martin C,
Hautefort A, Péchoux C, Bogaard HJ, Dorfmüller P, Remy S, Lecerf F,
Planté S, et al: Endothelial-to-mesenchymal transition in pulmonary
hypertension. Circulation. 131:1006–1018. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang JX, Pan YY, Zhao YY and Wang XX:
Endothelial progenitor cell-based therapy for pulmonary arterial
hypertension. Cell Transplant. 22:1325–1336. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen H, Strappe P, Chen S and Wang LX:
Endothelial progenitor cells and pulmonary arterial hypertension.
Heart Lung Circ. 23:595–601. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang XX, Zhang FR, Shang YP, Zhu JH, Xie
XD, Tao QM, Zhu JH and Chen JZ: Transplantation of autologous
endothelial progenitor cells may be beneficial in patients with
idiopathic pulmonary arterial hypertension: A pilot randomized
controlled trial. J Am Coll Cardiol. 49:1566–1571. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lan B, Hayama E, Kawaguchi N, Furutani Y
and Nakanishi T: Therapeutic efficacy of valproic acid in a
combined monocrotaline and chronic hypoxia rat model of severe
pulmonary hypertension. PLoS One. 10:e01172112015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Teicher BA and Fricker SP: CXCL12
(SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 16:2927–2931.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Miller RJ, Banisadr G and Bhattacharyya
BJ: CXCR4 signaling in the regulation of stem cell migration and
development. J Neuroimmunol. 198:31–38. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Peng SB, Zhang X, Paul D, Kays LM, Gough
W, Stewart J, Uhlik MT, Chen Q, Hui YH, Zamek-Gliszczynski MJ, et
al: Identification of LY2510924, a novel cyclic peptide CXCR4
antagonist that exhibits antitumor activities in solid tumor and
breast cancer metastatic models. Mol Cancer Ther. 14:480–490. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Farkas D, Kraskauskas D, Drake JI,
Alhussaini AA, Kraskauskiene V, Bogaard HJ, Cool CD, Voelkel NF and
Farkas L: CXCR4 inhibition ameliorates severe obliterative
pulmonary hypertension and accumulation of C-kit+ cells
in rats. PLoS One. 9:e898102014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Morimatsu Y, Sakashita N, Komohara Y,
Ohnishi K, Masuda H, Dahan D, Takeya M, Guibert C and Marthan R:
Development and characterization of an animal model of severe
pulmonary arterial hypertension. J Vasc Res. 49:33–42. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rondelet B, Kerbaul F, Motte S, van
Beneden R, Remmelink M, Brimioulle S, McEntee K, Wauthy P, Salmon
I, Ketelslegers JM and Naeije R: Bosentan for the prevention of
overcirculation-induced experimental pulmonary arterial
hypertension. Circulation. 107:1329–1335. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nishimura T, Vaszar LT, Faul JL, Zhao G,
Berry GJ, Shi L, Qiu D, Benson G, Pearl RG and Kao PN: Simvastatin
rescues rats from fatal pulmonary hypertension by inducing
apoptosis of neointimal smooth muscle cells. Circulation.
108:1640–1645. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bahmanpour S, Khozani Talaei T, Fard Zarei
N, Jaberipour M, Hosseini A and Esmaeilpour T: A comparison of the
multiple oocyte maturation gene expression patterns between the
newborn and adult mouse ovary. Iran J Reprod Med. 11:815–822.
2013.PubMed/NCBI
|
|
19
|
Stenmark KR, Meyrick B, Galie N, Mooi WJ
and McMurtry IF: Animal models of pulmonary arterial hypertension:
The hope for etiological discovery and pharmacological cure. Am J
Physiol Lung Cell Mol Physiol. 297:L1013–L1032. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Okada K, Tanaka Y, Bernstein M, Zhang W,
Patterson GA and Botney MD: Pulmonary hemodynamics modify the rat
pulmonary artery response to injury. A neointimal model of
pulmonary hypertension. Am J Pathol. 151:1019–1025. 1997.PubMed/NCBI
|
|
21
|
Abe K, Toba M, Alzoubi A, Ito M, Fagan KA,
Cool CD, Voelkel NF, McMurtry IF and Oka M: Formation of plexiform
lesions in experimental severe pulmonary arterial hypertension.
Circulation. 121:2747–2754. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kajstura J, Rota M, Hall SR, Hosoda T,
D'Amario D, Sanada F, Zheng H, Ogórek B, Rondon-Clavo C,
Ferreira-Martins J, et al: Evidence for human lung stem cells. N
Engl J Med. 364:1795–1806. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fang S, Wei J, Pentinmikko N, Leinonen H
and Salven P: Generation of functional blood vessels from a single
c-kit+ adult vascular endothelial stem cell. PLoS Biol.
10:e10014072012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim JY, Choi JS, Song SH, Im JE, Kim JM,
Kim K, Kwon S, Shin HK, Joo CK, Lee BH and Suh W: Stem cell factor
is a potent endothelial permeability factor. Arterioscler Thromb
Vasc Biol. 34:1459–1467. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ridzuan N, Al Abbar A, Yip WK, Maqbool M
and Ramasamy R: Characterization and expression of senescence
marker in prolonged passages of rat bone marrow-derived mesenchymal
stem cells. Stem Cells Int. 2016:84872642016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang X, Wu P, Huang F, Xu M, Chen M,
Huang K, Li GP, Xu M, Yao D and Wang L: Baicalin attenuates chronic
hypoxia-induced pulmonary hypertension via adenosine A2A
receptor-induced SDF-1/CXCR4/PI3K/AKT signaling. J Biomed Sci.
24:522017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Favre S, Gambini E, Nigro P, Scopece A,
Bianciardi P, Caretti A, Pompilio G, Corno AF, Vassalli G, von
Segesser LK, et al: Sildenafil attenuates hypoxic pulmonary
remodelling by inhibiting bone marrow progenitor cells. J Cell Mol
Med. 21:871–880. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Young KC, Torres E, Hatzistergos KE, Hehre
D, Suguihara C and Hare JM: Inhibition of the SDF-1/CXCR4 axis
attenuates neonatal hypoxia-induced pulmonary hypertension. Circ
Res. 104:1293–1301. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ling X, Spaeth E, Chen Y, Shi Y, Zhang W,
Schober W, Hail N Jr, Konopleva M and Andreeff M: The CXCR4
antagonist AMD3465 regulates oncogenic signaling and invasiveness
in vitro and prevents breast cancer growth and metastasis in vivo.
PLoS One. 8:e584262013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Galsky MD, Vogelzang NJ, Conkling P,
Raddad E, Polzer J, Roberson S, Stille JR, Saleh M and Thornton D:
A phase I trial of LY2510924, a CXCR4 peptide antagonist, in
patients with advanced cancer. Clin Cancer Res. 20:3581–3588. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Arakaki R, Tamamura H, Premanathan M,
Kanbara K, Ramanan S, Mochizuki K, Baba M, Fujii N and Nakashima H:
T134, a small-molecule CXCR4 inhibitor, has no cross-drug
resistance with AMD3100, a CXCR4 antagonist with a different
structure. J Virol. 73:1719–1723. 1999.PubMed/NCBI
|
|
32
|
Yang JX, Zhang N, Wang HW, Gao P, Yang QP
and Wen QP: CXCR4 receptor overexpression in mesenchymal stem cells
facilitates treatment of acute lung injury in rats. J Biol Chem.
290:1994–2006. 2015. View Article : Google Scholar : PubMed/NCBI
|
